Novo Nordisk A/S (NVO)
Pharmaceutical Preparations · market cap $169.8B · as of 2026-10-16
Research and calibrated estimates, not financial advice — verify before acting.
- 2026-12-14 (est.)Phase 2 · NNC0662-0419imp 7/10
- 2026-12-31 (est.)NDA Filing · Etavopivatimp 8/10
- 2027-01-14 (est.)Phase 2 · UBT251imp 7/10
- 2027-01-25 (est.)Phase 3 · Insulin Icodecimp 9/10
- 2027-01-29 (est.)Phase 3 · Ziltivekimabimp 9/10
- 2027-03-01 (est.)Phase 3 · CagriSema (Cagrilintide B and Semaglutide I)imp 9/10
- 2027-04-01 (est.)Otherimp 6/10
- 2027-05-12 (est.)Phase 3 · Cagrilintideimp 9/10
| Asset | Phase | Indication |
|---|---|---|
| NNC6019-0001 | Phase 3 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) |
| CDR132L | Phase 2 | Heart Failure |
| biphasic insulin aspart | Phase 3 | Diabetes |
| NNC109-0012 | Phase 2 | Inflammation |
| Cagrilintide | Phase 3 | Obesity or Overweight |
| Concizumab | Phase 3 | Congenital Bleeding Disorder |
| biphasic human insulin | Phase 3 | Diabetes |
| Insulin Icodec | Phase 3 | Diabetes Mellitus, Type 2 |
| Semaglutide (administered by PDS290 pen) | Phase 2 | Healthy Volunteers Diabetes Mellitus, Type 2 |
| human insulin | Phase 3 | Diabetes |
| insulin 338 (GIPET I) | Phase 2 | Diabetes |
| insulin NPH | Phase 3 | Diabetes |
| NNC0662-0419 | Phase 2 | Overweight |
| turoctocog alfa pegol | Phase 3 | Congenital Bleeding Disorder |
| rosiglitazone | Phase 3 | Diabetes |
| biphasic insulin aspart 50 | Phase 3 | Diabetes |
| DPP-4 inhibitor | Phase 3 | Diabetes |
| NNC0365-3769 (Mim8) | Phase 3 | Haemophilia A |
| Norditropin® | Phase 3 | Growth Hormone Deficiency in Children |
| Ziltivekimab B | Phase 3 | Cardiovascular Risk |
Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
- SEC filings — EDGAR filings for NVO (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.
